Aspira Women's Health Inc. (AWHL): Entry into a Material Definitive Agreement
Aspira Women's Health Inc. (AWHL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 awhl-20260706xex10d1.htm EX-10.1 SUBORDINATED BUSINESS LOAN AND SECURITY AGREEMENT THIS SUBORDINATED BUSINESS LOAN AND SECURITY AGREEMENT (as the same may be amended, restated, modified, or supplemented from time to time, this “ Agreement ”) dated as of July 01, 2
How this was made
The 30-second read
Why it matters
The agreement introduces a subordinated term loan with scheduled repayments, a default interest rate of +5.00% during an Event of Default, and a make-whole premium upon prepayment, all of which can influence credit spreads and equity risk premium.
Market read
This is a fresh, primary-source disclosure of new debt financing terms, which can change leverage and downside risk expectations even without immediate operational updates.
What to watch
Traders should verify the missing exhibit details (principal amount, interest rate in the Supplement, maturity, collateral scope, and any financial covenants) because those drive the real valuation and risk impact.
Background
The filing is an SEC Form 8-K reporting entry into a material definitive agreement, plus creation of a direct financial obligation.
Ticker impact
Aspira Women’s Health entered a material definitive subordinated business loan and security agreement, creating a new direct financial obligation.
Near-term trading impact is likely limited unless the filing includes principal size, interest rate, covenants, or collateral details elsewhere in the exhibit set.
The excerpt confirms entry into a material definitive agreement and includes default-rate and make-whole/prepayment concepts, but the principal amount, pricing, and covenant package are not shown in the provided text.
Market effects
Adds to the financing narrative for women’s health healthcare providers, where debt terms can influence perceived balance-sheet risk.
No clear regional spillover indicated in the provided excerpt.
No global macro or cross-border impact is evidenced in the provided text.
Counterpoint
If the loan is primarily for working capital with manageable covenants and favorable pricing, the market may view it as stabilizing rather than dilutive to risk.
Key entities
- issuerAspira Women’s Health Inc.
Parent company and borrower under the subordinated business loan and security agreement.
- lenderAgile Lending, LLC
Lead lender providing the term loan under the agreement.
- collateral_agentAgile Capital Funding, LLC
Collateral agent for the lenders under the agreement.
